Psyence Group’s Post

Between new data coming out of conferences, new insights into adalimumab biosimilars, and a study evaluating the impact of biosimilars on patient out-of-pocket costs, the biosimilar space had a very eventful March. https://lnkd.in/gvWPxFn3

Unlike other pivotal trials with only 24-months follow-up, the HORIZON trial evaluated MIGS outcomes with HYDRUS® Microstent over a period of 5 years. Learn more about the clinical efficacy of the HYDRUS® Microstent in our whitepaper: http://spr.ly/6046W01EA #ophthalmology #clinicalresearch

In drug discovery, many promising treatments get stuck in the "valley of death," the gap between candidate compounds and clinical implementation. Discover how Curia and the US National Institutes of Health (NIH) are transforming this landscape by uniting government, industry, and academic resources to overcome these obstacles. Explore C&EN’s white paper to gain insights from Curia and NIH experts: https://ow.ly/futx50SMyFh ------ Explore Curia’s strategic partnerships to advance drug research. Contact us: https://ow.ly/mXkv50SJcqK #DrugDiscovery #CDMO #PharmaInnovation #ClinicalResearch

Get to know the benefits of these partnerships, with insights and examples from NIH and Curia experts who have been involved for years. Key Objectives: How programs maximize collaboration and support Pairing deep expertise with unparalleled technology access How investment can unlock otherwise-missed potential https://lnkd.in/gnuMP2rs #WhatWeDoMatters #FromCuriositytoCure Curia

🧬ATMPs are highly innovative technologies developed as a result of a long, complex and often difficult research, development and market access process. 👩🔬As these transformative therapies come to the European market in greater numbers, and as their importance to the competitiveness of the Single Market is becoming increasingly apparent, we put together a short but comprehensive guide to the ATMP lifecycle, zeroing in on the complex processes and most significant hurdles developers must navigate at each stage of the cycle. 🔬Click here to find out what it takes to bring ATMPs to the lives of European patients: https://lnkd.in/eKhrXqwF #ATMPs #cellandgenetherapy #orphandrug #innovation

Thanks for having us LSX World Congress! Our CEO & Co-founder, Neel Patel, joined a panel to discuss the future of precision medicine. The conversation highlighted the growing recognition among stakeholders of the benefits that precision medicine offers. Although transitioning from traditional methods to precision medicine involves challenges—particularly with regulatory agencies and payers—the gap is closing, suggesting that these obstacles are diminishing. To overcome these challenges, fostering strong partnerships, engaging with regulatory bodies early, and demonstrating value and cost-effectiveness throughout clinical studies are key steps toward commercialising innovative precision medicine technologies. At ZiO Health, we're leading the way with real-time therapeutic drug monitoring to support precision dosing. #LSX2024 #precisionmedicine #therapeuticdrugmonitoring #medtech

✨ Exciting News from Harbour BioMed! Just now, Harbour BioMed released the annual financial results for the full year 2023. In the press release, Harbour BioMed reported a net profit for the first time, with a profit of US$22.8 million for the year ended 31 December 2023. Other financial highlights include:   ✨ Revenue: The revenue for the full year 2023 is US$89.5 million, which increased significantly by US$48.8 million, or 119.9%, compared with US$40.7 million for the year ended 31 December 2022. ✨ Research and development costs: The research and development expenses decreased by 66.6%, from US$135.1 million in 2022 to US$45.1 million in 2023. ✨ Administrative expenses: The administrative expenses decreased by 28.6%, from US$27.3 million in 2022 to US$19.5 million in 2023. Explore more details here: https://lnkd.in/gfGinG6F #HarbourBioMed #2023 #FinancialResults #Growth

"Our #DiffuSphere™ platform is designed to enable us to deliver the right drug to the right place at the right time with a precise PK profile, aiming to ensure patients receive safe, effective, and durable treatment," said #Eupraxia's (NASDAQ: EPRX) CEO, Dr. #JamesHelliwell. "We are excited about the broad-based potential of DiffuSphere™. The clinical data from #EoE and #OA, combined with our extensive non-clinical data showing precise delivery of numerous drugs in a broad array of target tissues, reinforces our optimism." https://lnkd.in/gX8fii4X

Explore the latest in #medtech and #biopharma! Discover how capital limitations, surgical trends and new regulations are shaping these sectors. Read the full industry outlook by RSM senior life sciences analysts Amanda Laskey and Brian Winne: https://rsm.buzz/3YeiJN3

SonoVascular's breakthrough in Chile just blew my mind. 🇨🇱 First-in-human trial of their SonoThrombectomy™ system? Successful. Patient discharged after just 48 hours? Incredible. This innovative approach to treating venous thromboembolism (VTE) could change everything. It's a perfect example of why Latin America is becoming a hotbed for MedTech innovation. Have you considered LATAM for your clinical trials? Let's chat about how to make it happen. #MedTechInnovation #ClinicalTrials #bioaccess